Literature DB >> 20159770

Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuth-ethanedithiol with tobramycin in liposomes.

Misagh Alipour1, Zacharias E Suntres, Robert M Lafrenie, Abdelwahab Omri.   

Abstract

OBJECTIVES: This study examined the activities of tobramycin and bismuth against quorum sensing, virulence factors and biofilms of Pseudomonas aeruginosa by co-encapsulating the agents in liposomes in order to achieve greater delivery of the agents.
METHODS: The inhibitory effects of the agents, in either their conventional (free) or vesicle-entrapped (liposomal) formulations, were assessed by measuring the changes in the quorum-sensing signal molecule N-acyl homoserine lactone, pyoverdine, pyocyanin, elastase, protease, chitinase, bacterial attachment and biofilms in vitro.
RESULTS: The effectiveness of tobramycin and bismuth was superior when they were co-administered as a liposomal formulation as measured by their ability to attenuate the production of N-acyl homoserine lactone, elastase (P < 0.01), protease (P < 0.05) and chitinase (P < 0.01). In the presence of non-lethal concentrations of free and liposomal tobramycin and bismuth, bacterial attachment was attenuated. Biofilm formation was also attenuated with free tobramycin and bismuth, yet, in the presence of liposomal tobramycin and bismuth, biofilm complexes could form but contained mostly dead bacteria. When established biofilms were treated with higher concentrations, free tobramycin and bismuth killed and detached bacteria, while the liposomal tobramycin and bismuth penetrated and killed bacteria in the cores of the biofilms.
CONCLUSIONS: These data suggest that treatment of P. aeruginosa with tobramycin and bismuth, as measured by the changes in quorum sensing, virulence factors and biofilms, is most effective when delivered as a liposomal formulation at a lower concentration compared with the free formulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20159770     DOI: 10.1093/jac/dkq036

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Nanomedicine in the Management of Microbial Infection - Overview and Perspectives.

Authors:  Xi Zhu; Aleksandar F Radovic-Moreno; Jun Wu; Robert Langer; Jinjun Shi
Journal:  Nano Today       Date:  2014-08-01       Impact factor: 20.722

Review 2.  Nanotechnology-based drug delivery systems for control of microbial biofilms: a review.

Authors:  Matheus Aparecido Dos Santos Ramos; Patrícia Bento Da Silva; Larissa Spósito; Luciani Gaspar De Toledo; Bruna Vidal Bonifácio; Camila Fernanda Rodero; Karen Cristina Dos Santos; Marlus Chorilli; Taís Maria Bauab
Journal:  Int J Nanomedicine       Date:  2018-02-27

3.  Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors.

Authors:  Mai Alhajlan; Moayad Alhariri; Abdelwahab Omri
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

Review 4.  Nanoparticle approaches against bacterial infections.

Authors:  Weiwei Gao; Soracha Thamphiwatana; Pavimol Angsantikul; Liangfang Zhang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-07-15

5.  Materials innovation for co-delivery of diverse therapeutic cargos.

Authors:  Megan E Godsey; Smruthi Suryaprakash; Kam W Leong
Journal:  RSC Adv       Date:  2013-12-21       Impact factor: 3.361

6.  Bacteriocin of Pediococcus acidilactici HW01 Inhibits Biofilm Formation and Virulence Factor Production by Pseudomonas aeruginosa.

Authors:  Da-Hye Lee; Bong Sun Kim; Seok-Seong Kang
Journal:  Probiotics Antimicrob Proteins       Date:  2020-03       Impact factor: 4.609

Review 7.  Current Trends in Development of Liposomes for Targeting Bacterial Biofilms.

Authors:  Zora Rukavina; Željka Vanić
Journal:  Pharmaceutics       Date:  2016-05-24       Impact factor: 6.321

Review 8.  Inhalable Antimicrobials for Treatment of Bacterial Biofilm-Associated Sinusitis in Cystic Fibrosis Patients: Challenges and Drug Delivery Approaches.

Authors:  Sylvia Natalie Kłodzińska; Petra Alexandra Priemel; Thomas Rades; Hanne Mørck Nielsen
Journal:  Int J Mol Sci       Date:  2016-10-09       Impact factor: 5.923

9.  In vitro and in vivo activities of ticarcillin-loaded nanoliposomes with different surface charges against Pseudomonas aeruginosa (ATCC 29248).

Authors:  Amir Gharib; Zohreh Faezizadeh; Masoud Godarzee
Journal:  Daru       Date:  2012-10-03       Impact factor: 3.117

10.  Baicalein attenuates the quorum sensing-controlled virulence factors of Pseudomonas aeruginosa and relieves the inflammatory response in P. aeruginosa-infected macrophages by downregulating the MAPK and NFκB signal-transduction pathways.

Authors:  Jing Luo; Jin-Liang Kong; Bi-Ying Dong; Hong Huang; Ke Wang; Li-Hong Wu; Chang-Chun Hou; Yue Liang; Bing Li; Yi-Qiang Chen
Journal:  Drug Des Devel Ther       Date:  2016-01-07       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.